A novel CISD2 mutation associated with a classical Wolfram syndrome phenotype alters Ca2+ homeostasis and ER-mitochondria interactions by Rouzier C et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Rouzier C, Moore D, Delorme C, Lacas-Gervais S, Ait-El-Mkadem S, Fragaki K, 
Burté F, Serre V, Bannwarth S, Chaussenot A, Catala M, Yu-Wai-Man P, 
Paquis-Flucklinger V. 
A novel CISD2 mutation associated with a classical Wolfram syndrome 
phenotype alters Ca2+ homeostasis and ER-mitochondria interactions. 
Human Molecular Genetics 
2017 
26(9), 1599-1611 
 
 
Copyright: 
© The Author 2017. Published by Oxford University Press. This is an Open Access article distributed under 
the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), 
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original 
work is properly cited. 
DOI link to article: 
https://doi.org/10.1093/hmg/ddx060  
Date deposited:   
25/05/2017 
O R I G I N A L A R T I C L E
A novel CISD2mutation associated with a classical
Wolfram syndrome phenotype alters Ca21
homeostasis and ER-mitochondria interactions
Ce´cile Rouzier1,†, David Moore2,†, Ce´cile Delorme3, Sandra Lacas-Gervais4,
Samira Ait-El-Mkadem1, Konstantina Fragaki1, Florence Burte´2,
Vale´rie Serre5, Sylvie Bannwarth1, Annabelle Chaussenot1, Martin Catala6,
Patrick Yu-Wai-Man2,7,8,‡ and Ve´ronique Paquis-Flucklinger1,*,‡
1Universite´ Coˆte d’Azur, CHU, Inserm, CNRS, IRCAN, France, 2Wellcome Trust Centre for Mitochondrial
Research, Institute of Genetic Medicine, International Centre for Life, Newcastle University, Newcastle upon
Tyne NE1 3BZ, UK, 3Fe´de´ration de Neurologie, Universite´ Pierre et Marie Curie et Groupe Hospitalier Pitie´-
Salpe^trie`re, Paris, France, 4Joint Centre for Applied Electron Microscopy, Nice Sophia-Antipolis University,
Nice, France, 5UMR7592 CNRS, Jacques Monod Institute, Paris Diderot University, Paris, France, 6UMR 7622
CNRS et UPMC et Fe´de´ration de Neurologie, Universite´ Pierre et Marie Curie et Groupe Hospitalier Pitie´-
Salpe^trie`re, Paris, France, 7Department of Clinical Neurosciences, School of Clinical Medicine, University of
Cambridge, Cambridge, UK and 8NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL
Institute of Ophthalmology, London, UK
*To whom correspondence should be addressed at: Pr.Ve´ronique Paquis-Fluckinger, IRCAN UMR CNRS 7284/INSERM U1081, Medicine School, 28 av de
Valombrose, 06107 Nice cedex 2, France. Tel: þ(33) 493377710; Fax: þ(33) 493377033; Email: paquis@unice.fr or patrick.yu-wai-man@ncl.ac.uk
Abstract
Wolfram syndrome (WS) is a progressive neurodegenerative disease characterized by early-onset optic atrophy and diabetes melli-
tus, which can be associated with more extensive central nervous system and endocrine complications. The majority of patients
harbour pathogenicWFS1mutations, but recessive mutations in a second gene,CISD2, have been described in a small number of
families with Wolfram syndrome type 2 (WFS2). The defining diagnostic criteria for WFS2 also consist of optic atrophy and diabetes
mellitus, but unlike WFS1, this phenotypic subgroup has been associated with peptic ulcer disease and an increased bleeding ten-
dency. Here, we report on a novel homozygousCISD2mutation (c.215A>G; p.Asn72Ser) in a Moroccan patient with an overlapping
phenotype suggesting that Wolfram syndrome type 1 and type 2 form a continuous clinical spectrum with genetic heterogeneity.
The present study provides strong evidence that this particularCISD2mutation disturbs cellular Ca2þhomeostasis with enhanced
Ca2þ flux from the ER to mitochondria and cytosolic Ca2þ abnormalities in patient-derived fibroblasts. This Ca2þ dysregulation was
associated with increased ER-mitochondria contact, a swollen ER lumen and a hyperfused mitochondrial network in the absence
of overt ER stress. Although there was no marked alteration in mitochondrial bioenergetics under basal conditions, culture of
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patient-derived fibroblasts in glucose-free galactose medium revealed a respiratory chain defect in complexes I and II, and a trend
towards decreased ATP levels. Our results provide important novel insight into the potential disease mechanisms underlying the
neurodegenerative consequences ofCISD2mutations and the subsequent development of multisystemic disease.
Introduction
Wolfram syndrome (WS, OMIM #222300), also known histori-
cally as DIDMOAD (Diabetes Insipidus, Diabetes Mellitus, Optic
Atrophy, Deafness), is an autosomal recessive disorder charac-
terized by the association of diabetes mellitus and early-onset
optic atrophy, which can occur in varying combinations with di-
abetes insipidus, sensorineural deafness, renal tract abnormali-
ties or neuropsychiatric disorders (1,2). The majority of patients
harbour pathogenic WFS1 mutations, but recessive mutations
in a second gene, CISD2 (CDGSH iron-sulfur domain-containing
protein 2), have been described in a few patients with Wolfram
syndrome type 2 (WFS2, OMIM #604928). Unlike WFS1, patients
with WFS2 have been reported to develop bleeding intestinal ul-
cers and defective platelet aggregation, in the absence of diabe-
tes insipidus and psychiatric disorders (3–5).
The CISD2 gene is located within a region on human chromo-
some 4q where a genetic component for human longevity has been
mapped through a comparative genome analysis of centenarian
siblings (6). ACisd2 knock-out model demonstrated that CISD2 defi-
ciency drives premature ageing in mice and that Cisd2 is an essen-
tial gene that regulates lifespan (7). Furthermore, an elevated level
of CISD2 in transgenic mice extends the healthy lifespan of animals
and delays age-associated neurodegenerative phenotypes in mice
(8). CISD2 encodes for a small protein that contains a transmem-
brane domain at the N-terminal and a single CDGSH domain at the
C-terminal. The protein forms a homodimer harbouring two
redox-active 2Fe-2S clusters (9). CISD2, which is also known as
Miner 1 or ERIS, is an integral membrane protein that localizes to
the mitochondria-associated ER membranes (MAMs) and the evi-
dence so far suggests a dynamic distribution between the ER and
the mitochondrial outer membrane (10). It has a role in maintain-
ing both the structural integrity and the functional cross-talk be-
tween the ER and mitochondria, which in turn is crucial for the
regulation of glucose homeostasis and insulin sensitivity (11,12).
Unlike Wolframin encoded by WFS1, whose functions have been
extensively studied, the biological functions of CISD2 still remain
incompletely defined. However, both proteins seem to share over-
lapping functions with pivotal roles in regulating intracellular Ca2þ
homeostasis, the ER stress response and autophagy (13–15).
Here, we report the identification of a novel homozygous CISD2
mutation (c.215A>G; p.Asn72Ser) in a patient with a “classical” WS
phenotype marked by childhood-onset insulin-dependent diabetes
mellitus and progressive visual failure secondary to optic atrophy,
but without peptic ulcers or defective platelet aggregation as reported
previously in affected CISD2 mutation carriers. We provide experi-
mental evidence implicating dysregulation of Ca2þhomeostasis and
disturbed ER-mitochondria interactions as key pathophysiological
determinants that ultimately contribute to the development and pro-
gression ofCISD2-mediated disease.
Results
Clinical case
A 45-year-old Moroccan man (V3) was referred to the neurology
clinic for the investigation of progressive cognitive and gait distur-
bances. He was born at term from consanguineous parents. His
father (IV1) had late-onset type 2 diabetes mellitus and his older
sister (V1) developed insulin-dependent diabetes mellitus at the
age of 8 years old with severe diabetic retinopathy. At the age of
40 years old, she suffered from a cerebrovascular accident and she
passed away following an acute lower limb peripheral arterial oc-
clusion complicated by a severe infection. The proband was diag-
nosed with insulin-dependent diabetes mellitus at 8 years of age.
He developed progressive visual impairment from the age of 33
years old, and this was initially ascribed to diabetic retinopathy.
He had two episodes of hypoglycaemic coma at the age of 38 and
41 years old, and a few months after the second episode, he devel-
oped neurological impairment with progressive cognitive distur-
bances, apathy, gait instability, urinary incontinence and
dysphagia. At his baseline assessment in the neurology clinic,
neurological examination showed cerebellar ataxia, myoclonic
tremor, dysarthria, dysexecutive syndrome and a pseudobulbar
affect. Brain MRI showed generalised cortical and cerebellar atro-
phy, and bilateral optic nerve atrophy. We also observed loss of
the normal hyperintense signal of the pituitary gland on T1-
weighted sequence although the patient did not present with fea-
tures of diabetes insipidus (Fig. 1). Ophthalmological examination
with fundoscopy and optical coherence tomography (OCT) re-
vealed bilateral optic atrophy without evidence of diabetic retinop-
athy. The patient’s visual acuity was 1/20 (right eye) and 1/10 (left
eye). He did not report any hearing problems. The patient did not
have a history of peptic ulcers or bleeding tendency and haemato-
logic testing was unremarkable with normal platelet aggregation
to ADP, collagen, ristocetin, adrenaline and arachidonic acid. An
abdominal CT scan revealed several cysts in the right kidney, but
none in the left kidney, liver, spleen and pancreas. There were no
associated urinary tract abnormalities and renal function was pre-
served with normal blood levels of creatinine and urea nitrogen.
Blood and tissue samples were obtained for further studies after
the patient had given informed consent.
Identification of a novel homozygous CISD2 variant in a
patient presenting with a classical wolfram syndrome
phenotype
The proband’s combination of childhood-onset diabetes melli-
tus and progressive bilateral optic atrophy complicated by more
extensive neurological impairment led us to screen genes in-
volved in WS. No mutations were found in WFS1, but CISD2 se-
quencing revealed a novel homozygous variant, c.215A>G
(p.Asn72Ser), in exon 2. His healthy mother (IV2) was heterozy-
gous for this variant whereas his healthy sister (V2) was wild-
type (Fig. 2A and B). This missense variant changes a highly-
conserved asparagine (Asn) into a serine (Ser) at amino acid po-
sition 72 (Fig. 2C). It was not found in 200 ethnically and geo-
graphically matched control chromosomes and in the following
SNP and exome databases: LOVD (http://lovd.euro-wabb.org/
home.php?select_db¼WFS1), dbSNP (http://www.ncbi.nlm.nih.
gov/sites/), EVS (http://evs.gs.washington.edu/EVS/), and ExAC
(http://exac.broadinstitute.org/). The c.215A>G variant was pre-
dicted to be “disease causing” based upon in silico analysis with
SIFT (http://sift.jcvi.org/) and Mutation Taster (http://www.muta
tiontaster.org/). Protein modelling indicates that the Asn
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residue at position 72 is located within a random coil region
of the cluster-binding domain. The p.Asn72Ser substitution
is predicted to alter the interactions necessary for the stabiliza-
tion of the cluster-binding domain, which in turn affects the re-
dox and functional properties of the CISD2 protein (Fig. 2D).
The c.215A>G (p.Asn72Ser) variant does not induce
CISD2 RNAmis-splicing or a reduction in CISD2 protein
levels
Three different deleterious CISD2 mutations have so far been re-
ported, (c.109G>C, c.103þ 1G>A and a whole exon 2 deletion),
Figure 2. Identification of a novel CISD2 variant (c.215A>G; p.Asn72Ser) in the proband. (A) Family pedigree with the solid symbols representing clinically affected indi-
viduals. (B) Sequence chromatograms of the proband, his mother and his healthy sister. (C) Cross-species protein conservation of CISD2 in the region of the altered
Asparagine amino acid at position 72. (D) In silico analysis of the CISD2 homodimeric model. The individual monomers have been coloured in pink and light blue. The
domain topology of the dimeric CISD2 complex consists of a six-stranded b sandwich, which forms an intertwined b cap, and a larger cluster-binding domain carrying
two 2Fe-2S clusters (one per protomer) that have been highlighted as grey spheres. The Asn72 residue (shown in red) is localized in a random coil region of the cluster-
binding domain and it forms potential hydrogen bonds with the neighbouring amino acids Leu73, Ile75, Asp123 and Asn124, which are represented in light blue, green,
yellow and dark blue, respectively. Our in silico modeling indicates that the p.Asn72Ser change alters the interactions necessary for the stabilization of the cluster-bind-
ing domains and this conformational change is predicted to affect the redox and functional properties of the CISD2 protein.
Figure 1. Brain magnetic resonance imaging of the proband. (A) Axial T1. Marked brainstem and cerebellar atrophy. (B) Axial T2 FLAIR. Cortical and subcortical atrophy
with ventricular enlargement. (C) Sagittal T1. Brainstem and cerebellar atrophy, and lack of the normal posterior hypophysis hyperintense signal (arrow).
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all of which have been shown to affect mRNA splicing (3–5). We
sequenced CISD2 cDNA from the patient’s fibroblasts and quan-
tified CISD2 protein levels by western blotting. Sequencing of
the 886bp RT-PCR product did not show RNA mis-splicing and
there was no decrease in CISD2 protein levels compared with
control fibroblasts (Fig. 3).
ER-mitochondrial Ca2þ flux is increased in patient-
derived fibroblasts
Cellular Ca2þ homeostasis was investigated in patient and con-
trol fibroblasts. To assess ER-mitochondrial Ca2þ flux, histamine
(100 mM) was used to induce IP3R-dependent ER Ca
2þ release
and the ensuing Ca2þ transients were quantified in the mito-
chondrial and cytosolic compartments with the Rhod-2-AM and
Fluo-4-AM dyes, respectively (Fig. 4A–E). Histamine-stimulated
peak mitochondrial Ca2þ levels were significantly increased in
the patient’s fibroblasts compared with controls, in keeping
with enhanced ER-mitochondrial Ca2þ transfer (Fig. 4C). Peak
cytosolic Ca2þ levels were significantly decreased (Fig. 4E), but
no significant differences in ER Ca2þ levels were observed in the
patient’s fibroblasts when compared with controls (Fig. 4F).
Basal cytosolic [Ca2þ] was measured with the Fura-2-AM dye,
followed by thapsigargin-induced ER Ca2þ depletion in the ab-
sence of extracellular Ca2þ. Basal cytosolic [Ca2þ] was signifi-
cantly increased in CISD2-deficient fibroblasts (Fig. 4G), whereas
peak cytosolic [Ca2þ] following thapsigargin treatment was not
significantly different when compared with controls (Fig. 4H).
The thapsigargin-sensitive Ca2þ stores, which are defined as the
difference between peak and basal cytosolic [Ca2þ], were de-
creased in the patient’s fibroblasts, although this difference did
not reach statistical significance (Fig. 4I).
ER-mitochondrial contact is increased in patient-derived
fibroblasts
ER-mitochondrial contact is critical for mitochondrial Ca2þ up-
take following ER Ca2þ release. Based on electron microscopy,
we found a marked increase in ER apposition to mitochondria
in the patient’s fibroblasts compared with controls (Fig. 5A),
which was confirmed by quantitative analysis (Fig. 5B). ER-
mitochondrial apposition was also assessed with live cell confo-
cal microscopy. Fibroblasts were transfected with GFP Sec61b to
visualise the ER and loaded with MitoTracker Red to label mito-
chondria. Z axis stacks were acquired for 3D-reconstruction.
Colocalisation analysis with the Manders’ Coefficient revealed a
significant increase in ER-mitochondria apposition in the pa-
tient’s fibroblasts compared with controls (Fig. 5C).
The patient’s fibroblasts also exhibited a larger lumen with a
swollen appearance in some areas (Fig. 5A), indicative of possi-
ble ER stress. We therefore investigated ER stress and UPR (un-
folded protein response) induction with qRT-PCR analysis of the
ER stress markers BIP (an IRE1 target gene) and CHOP (a pro-
apoptotic PERK target gene) in the patient’s fibroblasts, controls
and fibroblasts from one patient with WFS1 secondary to con-
firmed recessive WFS1 mutations. To assess activation of the
ATF6 pathway, XBP1 gene expression was also assessed (Fig.
5D). There was no evidence that the CISD2 c.215A>G
(p.Asn72Ser) mutation induced significantly elevated ER stress
levels unlike the WFS1 patient.
Mitochondrial morphology and OXPHOS function are
mildly affected in patient-derived fibroblasts
Electron microscopy did not reveal marked ultrastructural ab-
normalities in the patient’s mitochondria, which demonstrated
numerous, thin, well-defined cristae running perpendicularly to
the mitochondrial longitudinal axis, and with a regular pattern
of parallel organization (Fig. 5A). Mitochondrial network mor-
phology was imaged and quantified with live cell confocal mi-
croscopy following Mitotracker Red staining. Interestingly, both
the average length and volume of mitochondrial fragments
were significantly increased in the patient’s fibroblasts com-
pared with controls (Fig. 6A and B). Furthermore, analysis of the
distribution of the length and volume of mitochondrial frag-
ments confirmed a significant shift in mitochondrial morphol-
ogy in the patient’s fibroblasts towards larger mitochondrial
fragments for both length and volume, pointing towards a more
fused and elongated mitochondrial network compared with
controls (Fig. 6C).
Spectrophotometric analysis of the patient’s fibroblasts
cultivated in glucose medium revealed no respiratory chain
deficiency (Table 1A). Polarographic analysis showed both nor-
mal oxygen consumption and mitochondrial substrate oxida-
tion (Table 1C). Identical experiments were performed on
fibroblasts grown in a glucose-free medium containing galac-
tose. Galactose is a carbon source that feeds the glycolytic
pathway with low efficiency and as such cells are forced to
rely predominantly on OXPHOS for ATP production.
Spectrophotometric analysis of the patient’s fibroblasts culti-
vated in galactose medium revealed a respiratory chain defect
in complexes I and II (Table 1B). Polarographic analysis
showed enhanced consumption of oxygen, glutamate/malate,
succinate and G3P (Table 1D). There was a trend towards de-
creased ATP levels in the patient’s fibroblasts under both basal
conditions and 2-deoxy-D-glucose (2-DG), which inhibits gly-
colysis and activates OXPHOS (Fig. 6D). There were no signifi-
cant differences in the expression levels of key OXPHOS
proteins (ATP5A, UQCRC2, SDHB, COX II and NDUFB8) in the
patient’s fibroblasts compared with controls (Fig. 6E). There
was no evidence of mtDNA deletions or depletion in the pa-
tient’s fibroblasts (data not shown). Western blot analysis of
the apoptosis markers caspase 3 and poly (ADP-ribose) poly-
merase (PARP) did not indicate increased levels of apoptosis in
the patient’s fibroblasts (Fig. 6F).
Discussion
About 10% of patients with WS do not carry bi-allelic mutations
in WFS1 and the only other causative gene that has been identi-
fied to date in a few isolated cases worldwide is CISD2 (16).
Figure 3. Absence of CISD2 RNA mis-splicing and normal CISD2 protein levels in
the patient’s fibroblasts. (A) A 886bp amplicon was obtained from cDNAs using
primers in the 5’-UTR and 3’-UTR which allow the amplification of the 3 CISD2
exons. M: molecular weight marker, P: patient, C: control; (-) negative controlc.
(B) Western blot analysis with an anti-CISD2 antibody in fibroblasts from patient
(P) and 3 control individuals (C1-C3).
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We therefore sequenced CISD2 in a well-defined cohort of 25 pa-
tients whose phenotypes fulfilled the diagnostic criteria for WS,
but who had previously not been found to harbour pathogenic
WFS1 mutations. We identified a novel homozygous CISD2 vari-
ant (c.215A>G; p.Asn72Ser) and the corroborative evidence we
have provided all point towards its pathogenicity, namely: (i)
co-segregation of this variant with affected disease status in a
consanguineous family; (ii) the high degree of evolutionary con-
servation of the Asn amino acid residue located at position 72 in
the functionally important cluster-binding domain of the pro-
tein; (iii) the absence of the c.215A>G variant in normative SNP
and exome databases and; (iv) in silico evidence predicting a dis-
ease causing effect based on the induced conformational
change of the CISD2 homodimeric protein model. Recessive
CISD2 mutations have been only described so far in five families
from Jordan and Italy (3–5). Affected patients exhibited diabetes
mellitus, optic atrophy and high-frequency sensorineural hear-
ing loss. The initial reports suggested that other features of WS
such as diabetes insipidus and psychiatric disorders were ab-
sent in WFS2 (3,4). However, Rondinelli and colleagues have now
described a patient carrying a homozygous c.103þ 1 CISD2 mu-
tation who developed clinical and biochemical signs of diabetes
insipidus (5). Of note, all the patients with CISD2 mutations re-
ported to date have developed peptic ulcer disease and a signifi-
cant bleeding tendency, suggesting a possible genotype-
phenotype association that is peculiar to WFS2. In contrast, the
patient that we describe in this report with the c.215A>G mis-
sense CISD2 variant had the classical features of Wolfram syn-
drome type 1, namely early-onset diabetes mellitus and
progressive optic atrophy, but at the age of 45 years old, he had
not been diagnosed with peptic ulcer disease or significant hae-
matological abnormalities. His clinical course was further com-
plicated with a cluster of neurodegenerative features such as
cerebellar syndrome, myoclonic tremor, dysexecutive syn-
drome and a pseudobulbar affect, which have previously been
reported as part of WFS1, but not WFS2 phenotypes. The
Figure 4. Patient’s fibroblasts showed disturbed cellular Ca2þ homeostasis. (A) Imaging of cellular Ca2þ flux with Ca2þ sensitive fluorescent dyes. Representative images
demonstrating analysis of mitochondrial Ca2þ with the Rhod-2-AM (red) dye (a, b), and cytosolic Ca2þ with the Fluo-4-AM (green) dye (c, d), before and after histamine
stimulation. The relevant regions of interest were analysed using the Fiji open access software. (B) Representative traces of mitochondrial Ca2þ transients. (C) Analysis
of average peak mitochondrial Ca2þ following histamine stimulation. F indicates fluorescence and F0 indicates basal fluorescence. Data are mean6SEM (Control n¼35,
patient n¼15); * P0.05; two-tailed unpaired t test. (D) Representative traces of cytosolic Ca2þ transients. (E) Analysis of average peak cytosolic Ca2þ following histamine
stimulation. Data are mean6SEM (Control n¼ 24, patient n¼14); * P0.05; two-tailed unpaired t test. (F) Imaging with the D1ER probe. Representative images of the
patient’s fibroblasts expressing D1ER: CFP signal (a) and YFP signal (b). The reticular pattern is indicative of ER localization. Regions of interest were analysed using the
Fiji open access software. (G) Increased basal cytosolic [Ca2þ] in the patient’s fibroblasts compared with controls. Data are mean6SEM (n¼3); **P0.01; two-tailed
unpaired t test. (H) Analysis of peak cytosolic [Ca2þ] levels after thapsigargin-induced ER Ca2þ depletion. Data are mean6SEM (n¼ 3). (I) Comparison of thapsigargin
(Tg)-sensitive Ca2þ stores in the patient’s fibroblasts and controls. Data are mean6SEM (n¼3).
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patient’s brain MRI scan also revealed neuroradiological
changes seen in patients with confirmed pathogenic WFS1 mu-
tations, namely atrophy of the optic nerve, brainstem and cerebel-
lum, in addition to loss of the normal neurohypophyseal
hypersignal (16). These similarities are probably explained, at least
in part, by the substantial expression overlap of CISD2 and
Wolframin in the human brain (3,17). Interestingly, the proband
was found to have multiple cysts in his right kidney, which has
previously not been described in the context of WS. The absence
of a known family history of multicystic kidney disease, the iso-
lated nature of the patient’s renal cysts and the clinical history are
all compatible with a diagnosis of unilateral and segmental cystic
disease (18), and it is likely to represent an incidental co-
occurrence rather than a true causal association with the underly-
ing CISD2 mutation. Our data support the concept that WFS1 and
WFS2 constitute a continuous clinical spectrum with overlapping
phenotypes, and although CISD2 mutations are relatively rare,
this gene should be screened in patients manifesting the defining
features of WS, in particular early-onset diabetes mellitus and
optic atrophy, but in whom no pathogenic WFS1 mutations have
been conclusively identified.
Our experimental data indicate that the c.215A>G CISD2
mutation disturbs cellular Ca2þ homeostasis characterized by
enhanced Ca2þ flux from the ER to mitochondria and cytosolic
Ca2þ abnormalities. CISD2 deficiency has previously been
shown to disturb basal cytosolic and mitochondrial Ca2þ levels,
albeit with conflicting results and to varying degrees in the cel-
lular and animal models tested (11,15). No studies have as-
sessed the impact of CISD2 mutations on IP3R-dependent Ca
2þ
flux between the ER and mitochondrial compartments, which is
an important potential mechanism linking ER dysfunction with
mitochondrial impairment in WS (19). In the patient’s fibro-
blasts, Ca2þ flux from the ER to mitochondria was enhanced as
demonstrated by significantly increased peak mitochondrial
Ca2þ levels following IP3R-dependent ER Ca
2þ release. This ob-
servation is consistent with the increased basal mitochondrial
Ca2þ levels found Cisd2 deficient MEFs (15). In addition, basal cy-
tosolic [Ca2þ] was significantly increased in the patient’s
Figure 5. Increased ER-mitochondrial contacts observed in the patient’s fibroblasts. (A) Ultrastructural electron micrographs of fibroblasts from the patient (a-b) and
a control individual (c-d). The contact sites between the ER and mitochondria have been indicated with arrows. The swollen ER lumen found in the patient’s cells has
been highlighted with white asterisks. A higher magnification view of the typical mitochondrial morphology found in the patient’s fibroblasts has also been
provided (inset of panel a). Scale bar¼1lm. (B) Quantification of the number of ER-mitochondria contacts expressed in mm2, as a percentage of mitochondria with ER
contact sites, and as a percentage of the total mitochondria length adjacent to the ER normalized by mitochondrial perimeter. Data are mean6SEM (Control n¼10,
patient n¼10); ** P0.01; * P0.05; two-tailed unpaired t test. (C) Representative images of the ER and mitochondrial network (upper panels).
Colocalisation analysis was performed using the Huygens Essential Analyzer and expressed as Manders’ coefficient M1 (ER/Mitochondrial (Mito) colocalisation) and M2
(Mito/ER colocalisation) to compare the patient’s fibroblasts with controls (lower panels). Data are mean6SEM (Control n¼56, patient n¼26); *** P0.001; * P0.05;
two-tailed unpaired t test. (D) qRT-PCR analysis of the ER stress markers BIP, CHOP and total XBP1. Data are mean6SEM (n¼4); *** P0.001; * P0.05; two-tailed
unpaired t test.
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fibroblasts and this was coupled with a significant decrease in
the amplitude of cytosolic Ca2þ transients following IP3R-depen-
dent ER Ca2þ release. In agreement with previous studies, no
difference was observed in ER Ca2þ levels by direct assessment
with the D1ER probe (11,20). The disturbed Ca2þ homeostasis in
the patient’s fibroblasts is therefore not due to alterations in ER
Ca2þ levels. Interestingly, Lu and colleagues have described a sim-
ilar increase in cytoplasmic Ca2þ levels in induced pluripotent
stem cells (iPSC) of WS patients carrying pathogenic WFS1 mu-
tations, which in turn resulted in calpain activation (21).
Importantly, calpain activation has been associated with the de-
velopment of type 2 diabetes and the Ca2þ/calpain axis is
emerging as a crucial modulator of pancreatic b-cell function
both in health and disease (22). Although Lu and colleagues did
not report Ca2þ modification in WFS2-deficient cells, they did
observe calpain hyperactivation in RNAi-mediated knockdown
suggesting that it is a common molecular pathway altered in
WS patients (21). It is likely that different mechanisms result in
calpain hyperactivation in WS and our results suggest that
WFS2 mutations could cause calpain activation by increasing
cytosolic calcium levels. Of note, increased cytosolic Ca2þ levels
have been observed in pancreatic b-cells of patients with both
type 1 and type 2 diabetes, implying that the regulation of cal-
cium levels could prove a promising therapeutic target not only
for WS, but also for other more common complex disorders
characterised by ER dysfunction (23).
Several of the key folding chaperones in the ER are Ca2þ de-
pendent and decreased ER Ca2þ content has been linked to ER
stress and the induction of the UPR (15). Electron micrographs
of the patient’s fibroblasts showed an expansion of the ER
compartment with the lumen appearing swollen in some
areas. These morphological changes have been described in
cells undergoing ER stress and the UPR (24). The mRNA levels
of key ER stress pathway factors were therefore quantified, but
Figure 6. No evidence of major OXPHOS dysfunction or increased apoptosis in the patient’s fibroblasts. (A) Representative examples of the 3D-reconstructed mitochon-
drial networks in the patient’s fibroblasts and controls. Huygens Object Analyzer was used to determine the length and volume of each mitochondrial fragment.
(B) Analysis of average mitochondrial fragment length (left panel) and volume (right panel). Data are mean6SEM (Control n¼56, patient’s cells n¼26); *** P0.001;
two-tailed unpaired t test. (C) Distribution of mitochondrial fragment length (upper panel) and volume (lower panel). Data are mean6SEM (n>25); *** P0.0001; *
P0.05; two-tailed unpaired t test. (D) ATP content assessed under two conditions: glucose (Gluc) and 2-deoxy-D-glucose (2-Deoxy). Data are mean6SEM (n¼3); two-
tailed unpaired t test. (E) Expression level of OXPHOS proteins. Representative western blot of ATP5A, UQCRC2, SDHB, COX II and NDUFB8 proteins performed with fi-
broblast lysates obtained from two control individuals (C1, C2) and the patient (P). CI-CV; complex I-V. (F) Representative western blots of caspase 3 and PARP in
untreated controls (C1-C3) and the patient’s fibroblasts (P) (upper panel). The caspase 3 and PARP antibodies had previously been validated on an STS (staurosporin)-
treated control fibroblast (lower panel).
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no significant increase was found compared with controls.
These results are consistent with the absence of ER Ca2þ levels
dysregulation in the patient’s fibroblasts, but contrasts with
previous studies showing that Cisd2-deficient MEFs exhibit
signs of ER stress with the pathological hallmark being an ex-
pansion of the ER compartment in order to increase the capac-
ity to process the accumulated unfolded proteins (15,25).
Similarly, although no physical ER modification was observed
in pancreatic b-cells with WFS1 mutations, these cells did ex-
hibit signs of ER stress with an increase in CHOP expression
and a strong UPR response marked by the increased activity of
the three main UPR pathways, including PERK, IRE1, and ATF6
(diabetes shang 2014 923). The activation of the UPR is thought
to mediate the reduced insulin content in these cells and
Wolframin could act upstream of the UPR, likely in an effort to
maintain ER function under protein folding stress. Further
studies will be necessary to analyse the effects of Ca2þ homeo-
stasis dysregulation in cell lines established from patients har-
bouring other CISD2 mutations. However, it is conceivable that
ER stress induces membrane expansion through UPR-mediated
activation of lipid biosynthesis (26), and that the subsequent
increase in ER size is sufficient on its own to dampen the
stress response as a compensatory mechanism. The current
body of evidence supports the hypothesis that unresolved ER
stress leads to ER dysfunction, reduced processing of insulin
and ultimately b-cell failure and the development of overt dia-
betes (27).
Strikingly, both the analysis of ER-mitochondrial signal
colocalisation and electron microscopy suggested an increased
degree in ER-mitochondria contact, possibly at MAM interfaces,
in the patient’s fibroblasts. A central function of the MAM is the
efficient transfer of Ca2þ from the ER to mitochondria, which is
highly dependent on close apposition between these two organ-
elles (28,29). The increased ER-mitochondria contact observed
in the patient’s fibroblasts could therefore account for the in-
creased Ca2þ flux between these two organelles. The increased
areas of ER-mitochondrial contact is an intriguing observation
and this could be due to a number of factors, including ER stress
and dysregulation of the IP3R channel (14,15,30,31). Elevated ER
stress can probably be discounted as the patient’s fibroblasts
did not display increased levels of ER stress markers. CISD2 has
previously been shown to interact with the IP3R and Bcl-2-IP3R
interaction, in turn, negatively regulates IP3R-dependent Ca
2þ
transfer to mitochondria (13,32). The loss of these important
regulations in the presence of a dysfunctional CISD2 protein
could therefore trigger increased cytosolic [Ca2þ] and ER-
mitochondrial Ca2þ flux.
The transfer of Ca2þ from the ER to mitochondria regulates
mitochondrial bioenergetics and mitochondrial-mediated apo-
ptosis (33). Low level ER-mitochondrial Ca2þ transfer is
Table 1. Analysis of mitochondrial respiratory chain function in the patient’s fibroblasts. (A,B) Spectrophotometric analysis of mitochondrial
respiratory chain enzyme activities in glucose (A) and in galactose medium (B). CS, citrate synthase. Results are expressed as extreme absolute
values or absolute values for controls or patient, respectively. Values are expressed in nanomols of substrate per minute per milligram of pro-
teins (lowered values are in grey). (C,D) Polarographic analysis of the respiratory chain in glucose (C) and in galactose medium (D). G3P, glycerol
3-phosphate. The results have been expressed as extreme absolute values or absolute values for controls and the patient, respectively, in
nanomols of oxygen per minute per milligram of proteins
(A) Spectrophotometric analysis on fibroblasts cultivated in glucose medium
Enzymatic activities I II III IV V CS
Control values (nmol/min/mg of proteins) 9.0–27.1 18.5–54.0 57.4–176.2 109.9–350.0 22.0–46.2 74.7–161.1
Patient 21.9 43.2 148.6 317.8 33.2 133.3
(B) Spectrophotometric analysis on fibroblasts cultivated in galactose medium
Enzymatic activities I II III IV V CS
Control values (nmol/min/mg of proteins) 15.2–20.1 28.2–48.0 88.8–143.0 181.7–315.4 22.7–47.5 124.8–225.0
Patient 7.5 24.7 142.7 272.0 36.0 144.7
(C) Oxygraphic analysis on fibroblasts cultivated in glucose medium
Oxygen consumption
Intact cells Digitonin permeabilized cells
GlutamateþMalate Succinate G3P
Control values (nmol O2/min/mg of proteins) 5.90–13.80 8.00–16.60 8.00–15.80 4.90–13.50
Patient 9.00 13.88 11.57 12.22
D Oxygraphic analysis on fibroblasts cultivated in galactose medium
Oxygen consumption
Intact cells Digitonin permeabilized cells
GlutamateþMalate Succinate G3P
Control values (nmol O2/min/mg of proteins) 5.58 – 17.44 8.16 – 13.45 8.60 – 10.97 5.22 – 12.91
Patient 20.71 19.28 21.32 20.11
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necessary to maintain OXPHOS under basal conditions, but con-
tinuous mitochondrial Ca2þ uptake can compromise cellular
bioenergetics by consuming the proton motive force (34,35).
Immortalized Cisd2 deficient MEFs were found to have increased
mitochondrial Ca2þ loading under basal conditions, which was
associated with altered mitochondrial ultrastructure, increased
mitochondrial respiration and enhanced cellular ATP utilization
(15). In contrast, mitochondrial respiratory chain activity was
relatively preserved in the patient’s fibroblasts. OXPHOS anom-
alies were only unmasked when the cells were cultured in re-
strictive galactose medium with a defect in complexes I and II
becoming apparent together with an increase in oxygen con-
sumption, glutamate/malate, succinate and G3P. Similarly,
there was a trend towards decreased ATP levels in the patient’s
fibroblasts under both basal conditions and 2-DG, which inhibits
glycolysis, thereby placing the cell under greater metabolic
stress. Although no marked structural abnormalities were de-
tected on electron microscopy, the patient’s fibroblasts did ex-
hibit an elongated mitochondrial network when assessed with
MitoTracker live cell staining. Enlarged and elongated mito-
chondria have been observed in the diaphragm muscle and
myoblasts from Cisd2 deficient mutant mice (20). On the other
hand, transient CISD2 knockdown of less than 4 h in H1299 epi-
thelial cells had no demonstrable effect on mitochondrial net-
work morphology (13). Overall, these observations indicate that
CISD2 is not directly involved in mitochondrial network
dynamics, unlike key mediators such as the pro-fusion proteins
MFN2 and OPA1 (36). Although speculative, the elongated mito-
chondrial network in the patient’s fibroblasts is likely to be a
compensatory response, as part of the previously described
phenomenon of stress induced mitochondrial hyperfusion
(SIMH) (37).
In conclusion, we report a novel missense homozygous
CISD2 mutation in a patient with clinical features that differ
from previously reported WFS2 case reports, emphasizing the
disease spectrum of WS and the need for molecular confirma-
tion. Although further work is needed to dissect the pathways
that ultimately precipitate multisystemic neurodegeneration,
the mutant CISD2 protein exerts a deleterious influence on ER-
mitochondrial structure and function, providing additional lines
of evidence about the central importance of interorganellar in-
teractions in human health and disease.
Materials and Methods
Sequencing ofWFS1 and CISD2
The coding exons of WFS1 (NM_006005.3) and CISD2
(NM_001008388.4) were amplified with intronic primers by using
standard conditions. Primers and PCR conditions are available
on request. PCR products were purified with an Illustra
ExoProStar enzyme (GE Healthcare, England), processed with a
Figure 7. Schematic model highlighting the deleterious consequences of the CISD2 (c.215A>G; p.Asn72Ser) mutation. This mutation was associated with disturbed
Ca2þ homeostasis characterised by enhanced ER-mitochondrial Ca2þ flux and increased cytosolic [Ca2þ]. There was increased ER-mitochondrial interorganellar contact
in the absence of any major disturbance in OXPHOS dysfunction.
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BidDyeVR Terminator Cycle Sequencing kit (Thermo Fischer,
Foster City, CA, USA) and analyzed on an ABI 3130 XL auto-
mated sequencer (Applied Biosystems).
RT-PCR analysis
Total RNA was extracted from fibroblasts by using the Trizol re-
agent according to the manufacturer’s instructions and treated
by DNAse I (Invitrogen, Carlsbad, CA). cDNA synthesis was per-
formed using the Kit Transcriptor first strand cDNA Synthesis
(Roche, USA). The 3 exons of CISD2 were sequenced using pri-
mers in the 5’UTR (5’-AGCTTGGCCAGAGCGGA-3’) and 3’UTR
(5’-AACCAAATGCAGTTTGGAAGG-3’). Measuring ER stress was
performed by qRT-PCR using TaqMan Gene Expression Assays
(ThermoFisher, USA): XBP1 (Hs00231936_m1), CHOP (Hs0035
8796_g1), BIP (Hs00607129_gH) and HPRT (Hs99999909_m1). qRT-
PCR reactions were run in duplicate on a LightCycler 480 (Roche,
USA) and assays were repeated four times. Fibroblasts from 2
healthy subjects and one WS patient were used as controls. The
results were analysed by students t-test.
OXPHOS spectrophotometric measurements
Enzymatic spectrophotometric measurements of the OXPHOS
respiratory chain complexes and citrate synthase were per-
formed at 37 C on patient’s fibroblasts according to standard
procedures (38). Proteins were measured according to Bradford
microassay (39).
Polarographic study
Polarographic studies on fibroblasts of intact cell respiration and
digitonin (0.004%) permeabilized cells mitochondrial substrate
oxidation were carried out as previously described (38). Proteins
were measured according to Bradford microassay (39).
Western blotting
50 mg of total protein extracts, obtained as previously described
(40), were separated on an acrylamide gel by SDS-PAGE and
transferred to a PVDF membrane (Millipore, Saint-Quentin,
France). Specific proteins were detected by using rabbit
polyclonal anti-CISD2 (1/1000, Pierce#PA5-34545) and anti-
GAPDH (1/20000, Abcam #ab9485). A cocktail of anti-human to-
tal OXPHOS complex antibodies (Mitosciences, Eugene, USA)
was used at 1/1000. Anti-mouse or anti-rabbit secondary anti-
body (Dako) was used at 1/5000 and signals were detected using
a chemiluminescence system (Immobilon Western HRP
Chemilumiscent substrates, Millipore).
Mitochondrial DNA analysis
Total DNA was extracted using standard phenol chloroform ex-
traction procedure. Mitochondrial DNA quantification in fibro-
blasts was performed by real-time quantitative PCR adapted
from the method described by Sarzi et al. (41). Primers and con-
ditions are available on request.
Cell culture
Primary fibroblast cultures were established using standard
procedures in RPMI supplemented with 10% Fetal Bovine
Serum, 45lg/ml uridine and 275lg/ml sodium pyruvate.
Cultures were incubated at 37 C with 5% CO2. For galactose
conditions, medium was replaced 24h before experiments by
glucose-free medium containing 5 mM galactose and 5 mM
pyruvate (42).
In silico analysis of the homodimeric CISD2 structure
The 2.1 A˚ coordinate set for the C-terminal water-soluble
domain of Miner 1 (pdb code: 3fnv; residues 57-135) was down-
loaded. Swiss-Pdb Viewer 3.7 software was used to generate the
ribbon diagram of the homodimeric CISD2 complex and analyze
the structural and conformational disruptions induced by the
c.215A>G (p.Asn72Ser) CISD2 mutation.
Electron microscopy
For ultrastructural analysis, cells were fixed in 1.6% glutaralde-
hyde in 0.1 M phosphate buffer, rinsed in 0.1 M cacodylate buf-
fer, post-fixed for 1h in 1% osmium tetroxide and 1% potassium
ferrocyanide in 0.1 M cacodylate buffer to enhance the staining
of membranes. Cells were rinsed in distilled water, dehydrated
Table 2. Comparison of phenotypic characteristics found in Wolfram syndrome 1 and 2 and the proband. (X): presence; (-): absence; *: The onset
of optic atrophy was in mid-adulthood from the age of 33 years old, which is later than in the first decade of life as seen in ‘classical’ WS
Clinical
features
Wolfram syndrome type 1
WFS1 (OMIM #222300)
Wolfram syndrome type 2
CISD2 (OMIM #604928)
Proband
CISD2
Diabetes mellitus X X X
Optic atrophy X X Late-onset *
Sensorineural deafness X X –
Diabetes insipidus X Once –
Neurologic disorders X Abnormal nerve
conduction
Severe neurological impairment
with cognitive deficits, MRI abnormalities
Psychiatric disorders X Mood disorders Not formally assessed
Bladder dysfunction X X X
Hypogonadism X X –
Hematologic disorders – X –
Peptic ulcer – X –
Rheumatologic disorders – Once –
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in alcohols and lastly embedded in epoxy resin. Contrasted
ultrathin sections (70 nm) were analyzed under a JEOL 1400
transmission electron microscope mounted with a Morada
Olympus CCD camera.
Ca2þmeasurements
Fibroblast cell lines were seeded at 100,000 cells/dish on glass
bottom dishes (Willco, HBS-3522). Fluo-4-am (ThermoFisher)
and Rhod-2-am (ThermoFisher) were used to evaluate cytosolic
and mitochondrial Ca2þ, respectively. 4 mM Fluo-4-am was
loaded at 37 C for 15 min or 8 mM Rhod-2-am was loaded at
room temperature for 30 min. Cells were washed twice with
PBS and incubated in Tyrode’s solution (137 mM NaCl, 2.7 mM
KCl, 1 mM MgCl2, 0.2 mM Na2HPO4, 12 mM NaHCO3, 2 mM CaCl2,
10 mM Glucose, pH 7) for 15 min. Dynamic measurements of
cytosolic and mitochondrial Ca2þ were performed at room
temperature with a Nikon A1R inverted confocal microscope
equipped with a x60, 1.40 NA oil objective in resonant scan-
ning mode at 3.7fps for 5 min. After 1 min (providing basal
fluorescence) histamine (100 mM) was added to evoke IP3R
dependent ER Ca2þ release and the Ca2þ transient was moni-
tored. Image analysis was performed in Fiji, the background
was subtracted and Ca2þ levels were calculated as (F-Fo)/Fo
where F indicates fluorescence and Fo indicates basal
fluorescence.
The ER targeted fluorescence resonance energy transfer
(FRET) based probe D1ER was used to measure ER Ca2þ levels.
Cells were transiently transfected with D1ER 48 h before imag-
ing in opti-MEM (ThermoFisher) with GeneJuice Transfection
Reagent (Merck Millipore) and 2 mg of plasmid DNA (pcDNA-
D1ER was a gift from Amy Palmer & Roger Tsien). Cells were
washed twice with PBS and imaged in HBSS without phenol
red or Ca2þ and supplemented with 5 mM glucose and 25 mM
HEPES (Sigma-Aldrich) at pH 7.4. Live cell imaging was per-
formed at room temperature with a Nikon A1R inverted confo-
cal microscope equipped with a x60, 1.40 NA oil objective.
The filters used were a 457 nm excitation filter and two emission
filters: 482 nm for CFP and 540 nm for YFP. The FRET to CFP ra-
tio was calculated by ratioing the emission at 540 nm and
482 nm.
Cytosolic Ca2þ levels were determined using the ratiometric
Ca2þ sensitive fluorescent dye Fura-2-am at basal and following
thapsigargin induced ER Ca2þ depletion. Fibroblast cell lines
were seeded at 40,000 cells/well on black 96 well optical bottom
microplates (ThermoFisher) the day before the experiment.
Cells were loaded with 5mM Fura-2 (ThermoFisher) at 37 C for
1 h 30 min, then washed twice with PBS and incubated for a fur-
ther 30 min. Fluorescence was monitored on a VarioskanTM LUX
multimode microplate reader at emission wavelength 510 nm
following alternate excitations at 340 nm and 380 nm in HBSS
without phenol red or Ca2þ. ER Ca2þ depletion was triggered by
the addition of 1 mm thapsigargin. To calibrate the Fura-2 probe,
Rmin was determined by the addition of 2 mM ionomycin
(ThermoFisher) and 3 mM EGTA (Sigma-Aldrich), and Rmax was
determined by the addition of 2 mM ionomycin (ThermoFisher)
and 10 mM CaCl2 (Sigma-Aldrich). The standard equation was
used to calculate cytosolic [Ca2þ]: [Ca2þ]¼Kd x Q x [(R-Rmin)/
Rmax-R], where R is the 340/380 ratio, Rmin is the 340/380 ratio
under Ca2þ free conditions, Rmax is the 340/380 ratio under Ca
2þ
saturating conditions, Q is the ratio of emission intensity at
380 nm for Ca2þ free and Ca2þ saturated Fura-2 and Kd was as-
sumed to be 225 nM.
Mitochondria–ER interactions and morphological
analysis
Fibroblast cell lines were seeded at 100,000 cells/dish on glass
bottom dishes. GFP-Sec61b was transiently transfected to detect
the ER. Cells were transfected 24 h before imaging in opti-MEM
(ThermoFisher) with GeneJuice Transfection Reagent (Merck
Millipore) and 1 mg of plasmid DNA. Mitotracker red (75 nM,
ThermoFisher) was loaded at 37 C for 30 min to detect
mitochondria. Cells were washed twice with PBS and imaged in
MEM without phenol red (ThermoFisher) supplemented with
25 mM HEPES (Sigma-Aldrich). Live cells were imaged at
room temperature with a Nikon A1R inverted confocal micro-
scope equipped with a x60, 1.40 NA oil objective. Sixty nine
Z-stacks were acquired across the cell at 0.11 mM increments
using a high speed piezo Z stage. All image analysis were per-
formed in Huygens Essential Software (SVI). Images were
deconvolved and a 3D-reconstructed. Colocalisation of the ER
and mitochondria signals was quantified using the Manders’
coefficient. ER total volume and the length and volume of each
mitochondrial fragment was analysed in Huygens Object
Analyser.
ATP measurements
ATP levels were measured using the CellTiter-Glo Luminescent
Assay (Promega) according to the manufacturer’s instructions.
Fibroblast cell lines were seeded at 40,000 cells/well on 96 well
white microplates (Thermo Scientific). The cells were incubated
for 1 h 30 min at 37 C in either glucose (5 mM, Sigma-Aldrich)
or, 2-Deoxy-D-glucose (5 mM, Sigma-Aldrich). Following incuba-
tion, 90 mL buffer was removed and 100 mL of CellTiter-glo re-
agent was added to each well. Following 25 min incubation in
the dark with shaking, luminescence was measured on a
Luminoskan Ascent (Thermo Scientific) with a 1000 ms integra-
tion time. Luminescence signal was normalized to mg of protein
using the Bradford assay.
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